The invention relates to platinum and rhenium complexes of formula (I) that may be used as imaging agents. In particular, the invention relates to imaging agents, for example imaging agents for use in the imaging of peroxisomes. Certain embodiments of the invention relate to compounds per se. Other embodiments relate to a process for the preparation of compounds and to the use of compounds as imaging agents. (Formula (I)) ##STR00001##

A photoelectric conversion film according to the present disclosure includes a perovskite compound including a monovalent formamidinium cation, a Pb cation and an iodide ion, and a substance having Hansen solubility parameters satisfying a dispersion term δ.sub.D of 20±0.5 MPa.sup.0.5, a polar term δ.sub.P of 18±1 MPa.sup.0.5 and a hydrogen bonding term δ.sub.H of 11±2 MPa.sup.0.5.

A photoelectric conversion film according to the present disclosure includes a perovskite compound including a monovalent formamidinium cation, a Pb cation and an iodide ion, and a substance having Hansen solubility parameters satisfying a dispersion term δ.sub.D of 20±0.5 MPa.sup.0.5, a polar term δ.sub.P of 18±1 MPa.sup.0.5 and a hydrogen bonding term δ.sub.H of 11±2 MPa.sup.0.5.

Radiolabeled liposomes can be used in the treatment of cancer. These local therapies can be used to treat cancers including, but not limited to, lung cancer, breast cancer, colorectal cancer, prostate cancer, skin cancer, stomach cancer, bladder cancer, liver cancer, leukemia, lymphoma, ovarian cancer, pancreatic cancer, hepatocellular carcinoma, melanoma, sarcoma, head and neck cancer, glioma, glioblastoma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma, leptomeningeal metastases, and pediatric high-grade glioma.

Radiolabeled liposomes can be used in the treatment of cancer. These local therapies can be used to treat cancers including, but not limited to, lung cancer, breast cancer, colorectal cancer, prostate cancer, skin cancer, stomach cancer, bladder cancer, liver cancer, leukemia, lymphoma, ovarian cancer, pancreatic cancer, hepatocellular carcinoma, melanoma, sarcoma, head and neck cancer, glioma, glioblastoma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma, leptomeningeal metastases, and pediatric high-grade glioma.

Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.

The invention relates to a manganese (II) complex, its preparation method and use. The structure of the complex is (R1R2R3R4A)2[MnX4], wherein R1, R2, R3 and R4 are identical or different, independently selected from alkyl, aryl, or heteroaryl; said alkyl, aryl, or heteroaryl can be optionally substituted with a substituent, and the substituent is preferably alkyl, aryl or heteroaryl; A is N, P, or As; X is optionally F, Cl, Br, or I. The present invention also relates to an organic light emitting diode, its preparation method and use, wherein the manganese (II) complex of the invention is used as a dopant in the light-emitting layer. The prepared organic light emitting diode exhibits high electrical-to-optical conversion efficiency which can be used for flat-panel displays and illuminations.

The invention relates to a manganese (II) complex, its preparation method and use. The structure of the complex is (R1R2R3R4A)2[MnX4], wherein R1, R2, R3 and R4 are identical or different, independently selected from alkyl, aryl, or heteroaryl; said alkyl, aryl, or heteroaryl can be optionally substituted with a substituent, and the substituent is preferably alkyl, aryl or heteroaryl; A is N, P, or As; X is optionally F, Cl, Br, or I. The present invention also relates to an organic light emitting diode, its preparation method and use, wherein the manganese (II) complex of the invention is used as a dopant in the light-emitting layer. The prepared organic light emitting diode exhibits high electrical-to-optical conversion efficiency which can be used for flat-panel displays and illuminations.

A lithium ion secondary battery includes a cathode, an anode, and an electrolytic solution. The anode includes a cyclic compound and the cyclic compound includes one or more of a first cyclic compound, a second cyclic compound, and a third cyclic compound.

Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.